Skip to main content

Gilead Sciences Q3 FY2026 results

  • GILD · Nasdaq
  • Biotechnology
  • S&P 500
$168.08+0.08%Close 13 Nov 2026 · Market value $210.1B

Gilead Sciences reported revenue of $8.30 billion, up 6.8% from a year earlier, net income of $2.43 billion and diluted earnings per share of $1.94 against $2.43 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Gilead Sciences Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$8.30B$7.77B+6.8%
Gross profit$6.73B$6.20B+8.5%
Gross margin81.1%79.8%+1.3 pts
Operating income$3.46B$3.33B+4.1%
Operating margin41.7%42.8%−1.1 pts
Net income$2.43B$3.05B−20.4%
Diluted EPS$1.94$2.43−20.2%
Operating cash flow$5.04B$4.11B+22.6%
Capital expenditure$237.0M$147.0M+61.2%
Free cash flow$4.80B$3.96B+21.1%

Operating KPIs for the quarter

Gilead Sciences operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Product sales$8.3Bup 12.9%
Biktarvy revenue$4.1Bup 10.1%
Descovy revenue$1.0Bup 49.2%
Trodelvy revenue$506.0Mup 41.7%
Genvoya revenue$339.0Mdown 10.1%
Vemlidy revenue$333.0Mup 18.9%
Yeztugo revenue$305.0Mup 682.1%
Yescarta revenue$294.0Mdown 15.8%
Odefsey revenue$286.0Mup 3.2%
Sofosbuvir/Velpatasvir revenue$274.0Mdown 11.3%
Livdelzi revenue$203.0Mup 93.3%
Symtuza - Revenue share revenue$132.0Mup 6.5%
AmBisome revenue$99.0Mdown 19.5%
Veklury revenue$86.0Mdown 69.0%
Tecartus revenue$60.0Mdown 27.7%
Royalty, contract and other revenues$11.0Mdown 97.4%
United States revenue$6.4Bup 20.5%
Europe revenue$1.1Bdown 31.5%
Rest of World revenue$872.0Mdown 6.5%

Earlier quarters

Gilead Sciences results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$8.30B+6.8%$1.94
Q2 FY202630 Jun 2026$7.80B+10.2%−$8.45
Q1 FY202631 Mar 2026$6.96B+4.4%$1.61
Q4 FY202531 Dec 2025$7.92B+4.7%$1.74
Q3 FY202530 Sep 2025$7.77B+3.0%$2.43
Q2 FY202530 Jun 2025$7.08B+1.8%$1.56
Q1 FY202531 Mar 2025$6.67B−0.3%$1.04
Q4 FY202431 Dec 2024$7.57B+6.4%$1.39

More on Gilead Sciences: financial statements · revenue · earnings per share

GILD's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.